Tag: Obstructive Sleep Apnea (OSA)
F&P fields questions on mask pipeline, tariff impact
May 27, 2026Liz Beaulieu, Editor
AUCKLAND, New Zealand – Analysts pressed Fisher & Paykel Healthcare executives during a recent earnings call on the company’s lack of new full-face mask launches for obstructive sleep apnea (OSA), even as other product categories continue to gain traction.
Analyst Ben Crozier described the full-face mask category as “a bit of a headwind” for F&P, noting it has been offset by more recent and frequent launches in other categories, including the F&P Solo (nasal), F&P Nova...
Apnimed backs OSA pill with two new peer-reviewed articles
May 19, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has published two peer-reviewed articles on AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg), an investigational, once-daily oral pill taken at bedtime designed to improve oxygenation and target the neuromuscular root cause of obstructive sleep apnea (OSA). The Phase 3 SynAIRgy trial results are published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), alongside a companion mechanistic review article in the American Journal of Respiratory...
Resmed teams with ŌURA to ‘turn insight into action’
May 19, 2026HME News Staff
SAN DIEGO – Resmed and smart ring maker ŌURA are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health, the companies say.
By connecting consumer-generated wellness insights with Resmed’s sleep health resources, the two companies say they are helping ŌURA members take a more informed next step to better understand their sleep health.
"We're at an inflection point in how people engage...
Researchers to compare three most common treatments for sleep apnea for effectiveness
May 12, 2026HME News Staff
TUCSON, Az. – University of Arizona researchers will use a five-year, nearly $14 million award from the Patient-Centered Outcomes Research Institute (PCORI) to support a clinical trial comparing three common treatments for obstructive sleep apnea (OSA) for effectiveness. The three treatments: CPAP therapy, dental devices and oral medication. "Sleep apnea can significantly affect quality of life and is costly to the workforce through lost productivity," said Dr. Sairam Parthasarathy,...
Philips continues to lean on international sleep growth, as FDA path continues
May 8, 2026Liz Beaulieu, Editor
AMSTERDAM – The Sleep and Respiratory Care (SRC) business at Philips grew in the low single digits in the first quarter of 2026, but its obstructive sleep apnea (OSA) portfolio stood out with double-digit growth outside of the U.S., says CEO Roy Jakobs.
International markets fuel OSA growth
OSA growth was particularly strong in Japan, the company’s second-largest market, Jakobs said during a recent conference call to discuss the company’s financial results.
“If you...
Nationwide Medical expands reach with DHS acquisition
April 27, 2026HME News Staff
CALABASAS, Calif. – Nationwide Medical has acquired Dynamic Healthcare Services (DHS), expanding access to its offerings across a wider geographic footprint.
DHS is a well-established provider of home respiratory supplies, durable medical equipment (DME) and oxygen across Pennsylvania, New Jersey and surrounding areas. It offers patient-centric services and clinical programming to drive improved outcomes in OSA and COPD therapies.
“Today’s announcement represents an exciting...
ProSomnus: ‘We are enabling smart sleep medicine’
April 14, 2026HME News Staff
SAN FRANCISCO – ProSomnus Sleep Technologies has announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The company says the RPMO2 OSA Device is the first theranostic device for sleep medicine, incorporating both precision oral appliance therapy and multi-night physiologic monitoring in one device. With this new clearance, it says the device is positioned as...
Dreem Health earns spot on Amazon Health Benefits Connector
April 13, 2026HME News Staff
NEW YORK – Dreem Health, a virtual sleep clinic managed by Sunrise Group, says it has become the first sleep care service to join Amazon’s Health Benefits Connector.
Amazon customers eligible for insurance-covered sleep services can now discover and enroll in Dreem Health’s personalized care when browsing for health care services.
“Millions of people live with undiagnosed sleep disorders that quietly impact their health, productivity, and quality of life,” said...
Researchers develop algorithm to predict impact of CPAP therapy on cardiovascular disease
April 13, 2026HME News Staff
NEW YORK – Researchers at Mount Sinai have created an analytic tool using machine learning that they say can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, according to findings recently published in Communications Medicine.
The researchers used a machine learning algorithm to create an analysis model that they say predicts how CPAP could affect an individual’s cardiovascular health – estimating each patient’s likeliness of benefit...
Apnimed secures $150M in debt financing ahead of planned launch of pill to treat OSA
April 7, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company developing oral therapies for obstructive sleep apnea (OSA), has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (HCRx). The company plans to use the capital to support commercial readiness activities and the planned U.S. launch of its lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA). "HCR is a highly respected health care...